SPAN

Powur Expands its Platform Offering with SPAN Smart Electrical Panel

Retrieved on: 
Thursday, July 13, 2023
Hardware, Alternative Energy, Energy, Technology, Utilities, Partnership, EV, Nintendo of America, Inc. vs. Blockbuster LLC., NEM, Solar energy, Renewable energy, Video game, PBC, SPAN

Powur PBC , a platform-based company simplifying the path to clean energy, announced it is adding the smart electrical panel (SPAN® Panel) and EV charger (SPAN Drive™) from SPAN , the leading innovator in home electrification technology, to its extensive portfolio of high-quality and innovative clean energy products available on its platform.

Key Points: 
  • Powur PBC , a platform-based company simplifying the path to clean energy, announced it is adding the smart electrical panel (SPAN® Panel) and EV charger (SPAN Drive™) from SPAN , the leading innovator in home electrification technology, to its extensive portfolio of high-quality and innovative clean energy products available on its platform.
  • “By partnering with SPAN, Powur is adding innovative new technology to our platform that empowers people to electrify their homes and manage energy like never before, achieving a new level of energy freedom.”
    SPAN revolutionized the hundred-year-old electrical panel with its award-winning SPAN Panel, providing circuit-level management, real-time monitoring, and actionable insights through its SPAN Home® app.
  • SPAN Panel enhances the value of various clean energy products offered by Powur, giving people greater control and insight into their home’s energy system.
  • In addition, Powur is offering SPAN Drive, a level-2 EV charger that integrates intelligently with the home energy system.

First Wave BioPharma Announces Initial Topline Results from Phase 2 SPAN Clinical Trial Investigating Enhanced Adrulipase Formulation

Retrieved on: 
Thursday, July 13, 2023
Biologics license application, EPI, CFA, Exocrine pancreatic insufficiency, Clinical trial, BOCA, First wave, CNA, Arbutus Biopharma, Patient, Data, Cystic fibrosis, SPAN, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, Food, Safety, Malabsorption, Medical imaging, Pharmaceutical industry

Initial data from the study indicate the enhanced adrulipase formulation was safe and well tolerated and demonstrated an improvement over prior formulations of adrulipase.

Key Points: 
  • Initial data from the study indicate the enhanced adrulipase formulation was safe and well tolerated and demonstrated an improvement over prior formulations of adrulipase.
  • First Wave BioPharma is continuing to assess the data and expects to report additional findings on primary and secondary endpoints in approximately eight weeks.
  • The Phase 2 SPAN clinical trial was designed to investigate the safety, tolerability and efficacy of an enteric microgranule delivery formulation for adrulipase in a titrated dose-escalation study involving thirteen (13) patients.
  • “Preliminary data from the Phase 2 SPAN clinical trial indicate our enhanced microgranule delivery formulation of adrulipase was safe and well tolerated,” said James Sapirstein, President and CEO of First Wave BioPharma.

First Wave BioPharma Chairman and CEO Issues Letter to Stockholders

Retrieved on: 
Wednesday, July 5, 2023
Biologics license application, Patent, Intellectual property, Letter, EPI, Food, CFA, Exocrine pancreatic insufficiency, United States Patent and Trademark Office, Clinical trial, BOCA, Quality of life, First wave, Cystic fibrosis, Patent Cooperation Treaty, IP, CNA, PCT, Stomach, PERT, Public expenditure, World Organization of the Scout Movement, Capsule, Patient, Cystic Fibrosis Foundation, WIPO, Growth, SPAN, Health, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, CF, BLA, Safety, Gastrointestinal disease, Malabsorption, Pharmaceutical industry, Holding company, Shareholder

BOCA RATON, Fla., July 05, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President and CEO of First Wave BioPharma, has issued a Letter to Stockholders providing an update on the Company’s clinical programs and recent events.

Key Points: 
  • BOCA RATON, Fla., July 05, 2023 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today announced that James Sapirstein, Chairman, President and CEO of First Wave BioPharma, has issued a Letter to Stockholders providing an update on the Company’s clinical programs and recent events.
  • We are pleased to announce that the last patient in the study has completed their last visit.
  • On June 22, 2023, First Wave held its 2023 Annual Meeting of Stockholders (the “Annual Meeting”) during which stockholders had the opportunity to vote on five proposals.
  • As always, I extend my appreciation to our stockholders for your continued support.

First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation

Retrieved on: 
Wednesday, June 28, 2023
EPI, Food, CFA, Exocrine pancreatic insufficiency, Clinical trial, BOCA, First wave, CNA, PERT, Patient, Cystic fibrosis, SPAN, CF, Safety, Malabsorption, Pharmaceutical industry

The Phase 2 multi-center clinical trial ( NCT05719311 ) is designed to investigate the safety, tolerability and efficacy of an enteric microgranule delivery formulation for adrulipase in a titrated dose-escalation study involving thirteen (13) patients.

Key Points: 
  • The Phase 2 multi-center clinical trial ( NCT05719311 ) is designed to investigate the safety, tolerability and efficacy of an enteric microgranule delivery formulation for adrulipase in a titrated dose-escalation study involving thirteen (13) patients.
  • The primary efficacy endpoint is the coefficient of fat absorption (CFA), with secondary endpoints of stool weight, signs and symptoms of malabsorption and coefficient of nitrogen absorption (CNA).
  • “Dosing the final patient is a key milestone in the Phase 2 SPAN clinical trial investigating our enhanced enteric microgranule delivery formulation of adrulipase for the treatment of EPI in CF patients,” said James Sapirstein, President and CEO of First Wave BioPharma.
  • Each patient will be started on a low dose of adrulipase.

First Wave BioPharma Strengthens Intellectual Property Estate

Retrieved on: 
Tuesday, June 27, 2023
Patent, EPI, CFA, Exocrine pancreatic insufficiency, United States Patent and Trademark Office, BOCA, First wave, Patent Cooperation Treaty, IP, PCT, CNA, World Organization of the Scout Movement, Publication, Patient, Cystic fibrosis, WIPO, SPAN, CFA Institute, Safety, Malabsorption, Pharmaceutical industry

The PCT includes 157 countries and covers virtually all worldwide industrialized markets.

Key Points: 
  • The PCT includes 157 countries and covers virtually all worldwide industrialized markets.
  • “The patent publications for our enhanced enteric microgranule delivery formulation of adrulipase and its use for the treatment of malabsorption highlight First Wave’s ability to introduce important drug innovations for the treatment of underserved disease indications,” said James Sapirstein, President and CEO of First Wave BioPharma.
  • The Phase 2b SPAN trial is designed to investigate the safety, tolerability, and efficacy of a new enteric microgranulation formulation of adrulipase.
  • Patients will be screened at baseline to ensure that they have a coefficient of fat absorption (CFA) of at least 80%.

First Wave BioPharma Reaches Enrollment Target for Phase 2 SPAN Adrulipase Clinical Trial in Cystic Fibrosis

Retrieved on: 
Tuesday, June 13, 2023
EPI, CFA, Exocrine pancreatic insufficiency, Clinical trial, First wave, CNA, Patient, Cystic fibrosis, SPAN, CFA Training College, Safety, Malabsorption, Pharmaceutical industry

The Phase 2 multi-center clinical trial ( NCT05719311 ) is designed to investigate the safety, tolerability and efficacy of an enteric microgranule delivery formulation for adrulipase in a titrated dose-escalation study involving an estimated twelve (12) patients.

Key Points: 
  • The Phase 2 multi-center clinical trial ( NCT05719311 ) is designed to investigate the safety, tolerability and efficacy of an enteric microgranule delivery formulation for adrulipase in a titrated dose-escalation study involving an estimated twelve (12) patients.
  • James Sapirstein, Chief Executive Officer of First Wave BioPharma commented, “We are very pleased to have reached the enrollment target in our Phase 2b SPAN study of adrulipase.
  • The Phase 2b SPAN trial is designed to investigate the safety, tolerability, and efficacy of a new enteric microgranulation formulation of adrulipase.
  • The SPAN trial is an open-label study that will be conducted at three sites in the U.S. A total of 13 cystic fibrosis patients, all 18 years or older have been enrolled.

Uplight Announces New Members of its Senior Leadership Team

Retrieved on: 
Wednesday, May 17, 2023
Technology, Environment, Utilities, Sustainability, Energy, Software, SEPA, Intellectual property, Employment, Senior, General counsel, Google Nest, European Distributed Energy Partnership, Ohri, Pepco Holdings, Customer, Organization, The Electric Company, DEI, SPAN, Ecosystem, Pacific Gas and Electric Company, Management, Renewable energy, Exelon

Uplight , the technology partner of energy providers transitioning to a decarbonized future, today announced an expansion of its executive leadership team by appointing Shaila Lakhani Ohri as Senior Vice President and General Counsel and Hannah Bascom as Chief Market Innovation Officer.

Key Points: 
  • Uplight , the technology partner of energy providers transitioning to a decarbonized future, today announced an expansion of its executive leadership team by appointing Shaila Lakhani Ohri as Senior Vice President and General Counsel and Hannah Bascom as Chief Market Innovation Officer.
  • With Ohri’s legal experience providing strategic counsel across Exelon’s businesses and Bascom’s expertise leveraging technology and partnerships to move the industry forward, Uplight is poised to accelerate its transformational impact.
  • “Shaila and Hannah are strategic additions for Uplight at this critical moment, as we are positioned to scale our execution at the intersection of customer engagement and load management,” said Luis D’Acosta, CEO of Uplight.
  • “Their talent, experience and customer-centricity will be critical as we expand our solutions, add further capabilities and increase our impact.

First Wave BioPharma Completes Patient Screening For Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis

Retrieved on: 
Thursday, May 11, 2023
EPI, CFA, Exocrine pancreatic insufficiency, Clinical trial, BOCA, First wave, CNA, Patient, Cystic fibrosis, SPAN, CFA Training College, Safety, Malabsorption, Pharmaceutical industry

The Phase 2 multi-center clinical trial ( NCT05719311 ) is designed to investigate the safety, tolerability and efficacy of an enteric microgranule delivery formulation for adrulipase in a titrated dose-escalation study involving an estimated twelve (12) patients.

Key Points: 
  • The Phase 2 multi-center clinical trial ( NCT05719311 ) is designed to investigate the safety, tolerability and efficacy of an enteric microgranule delivery formulation for adrulipase in a titrated dose-escalation study involving an estimated twelve (12) patients.
  • James Sapirstein, Chief Executive Officer of First Wave BioPharma commented, “We are very pleased to have completed patient screening in our Phase 2b SPAN study of adrulipase.
  • The SPAN trial is an open-label study that will be conducted at three sites in the U.S. A total of 12 cystic fibrosis patients, 18 years or older are expected to be enrolled.
  • Each patient will be started on a low dose of adrulipase.

Together New Orleans and Solar Alternatives have joined forces to introduce the Community Lighthouse initiative featuring two new solar-powered neighborhood shelters

Retrieved on: 
Wednesday, May 3, 2023
Bethlehem Lutheran Church, Emergency, Education, Tesla Powerwall, Carbon, Walking, Economic development, Air conditioning, SPAN, Rest, Electric battery, Renewable energy, Broadmoor Hospital, Core city

NEW ORLEANS, May 3, 2023 /PRNewswire/ -- Together New Orleans and Solar Alternatives unveiled two new solar-powered neighborhood shelters in Broadmoor and Central City on March 25, 2023.

Key Points: 
  • NEW ORLEANS, May 3, 2023 /PRNewswire/ -- Together New Orleans and Solar Alternatives unveiled two new solar-powered neighborhood shelters in Broadmoor and Central City on March 25, 2023.
  • These shelters are part of the Community Lighthouse initiative, which strives to create 86 safe havens within a 15-minute walking distance from every address in the city.
  • The Broadmoor Community Church and Bethlehem Lutheran Church have been converted into resiliency hubs with charging stations capable of supporting light medical equipment.
  • The solar systems at these hubs were designed, installed, and will be maintained by Solar Alternatives and are the first two completed Community Lighthouse projects.

First Wave Biopharma Exceeds 50% Enrollment Target for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis

Retrieved on: 
Tuesday, April 25, 2023
EPI, CFA, Exocrine pancreatic insufficiency, Clinical trial, BOCA, First wave, CNA, Patient, Cystic fibrosis, SPAN, CFA Training College, Safety, Malabsorption, Pharmaceutical industry

The Phase 2 multi-center clinical trial ( NCT05719311 ) is designed to investigate the safety, tolerability and efficacy of an enteric microgranule delivery formulation for adrulipase in a titrated dose-escalation study involving an estimated twelve (12) patients.

Key Points: 
  • The Phase 2 multi-center clinical trial ( NCT05719311 ) is designed to investigate the safety, tolerability and efficacy of an enteric microgranule delivery formulation for adrulipase in a titrated dose-escalation study involving an estimated twelve (12) patients.
  • James Sapirstein, Chief Executive Officer of First Wave BioPharma, commented, “We are very pleased to have reached the half-way mark of enrollment in our SPAN study of adrulipase.
  • This represents an important milestone for First Wave and demonstrates that we are on track to complete enrollment in 1H’23 and report topline data in July 2023.
  • The SPAN trial is an open-label study that will be conducted at three sites in the U.S. A total of 12 cystic fibrosis patients, 18 years or older are expected to be enrolled.